%0 Journal Article
%T Upregulation of Serum Vascular Endothelial Growth Factor in Patients with Salivary Gland Tumor
%A Azadeh Andisheh Tadbir
%A Bijan Khademi
%A Mahyar Malekzadeh
%A Maryam Mardani
%A Bahar Khademi
%J Pathology Research International
%D 2013
%I Hindawi Publishing Corporation
%R 10.1155/2013/740582
%X Neoangiogenesis is essential for tumor development, invasion, and dissemination. The most potent of the cytokines associated with angiogenesis is vascular endothelial growth factor (VEGF). The aim of the present study was to determine VEGF serum level in patients with salivary gland tumor. Using an ELISA kit, the circulating levels of VEGF in sera from 58 patients with salivary gland tumor and 30 healthy controls were assessed. Mean VEGF levels in sera of patients with salivary gland tumors (574.9 ¡À 414.3) were significantly higher than those in controls (263.9 ¡À 310.0) ( ). Within the salivary gland tumor group, mean serum VEGF concentration in malignant tumors ( ) was 727.3 ¡À 441.8£¿pg/mL, and that in benign tumors ( ) was 442.2 ¡À 343.3£¿pg/mL. Mean serum VEGF concentration was significantly higher in malignant tumors than in benign tumors ( ) and was higher in benign tumors than in controls ( ). The data in the present study clearly show that VEGF level was consistently upregulated in benign and malignant tumors in comparison to healthy controls. However, the role of VEGF as a prognostic factor in salivary gland tumor and its application in antiangiogenic therapy require further clinical research. 1. Introduction Neoangiogenesis, the development of new vessels from pre-existing ones, is necessary for tumor development, invasion, and dissemination. Angiogenic process not only delivers nutrients for tumor growth but also increases the chance for tumor cells to enter the circulation and metastasis [1]. A variety of signals such as diminished nutrition or oxygen in tissue or genetic changes in oncogenes or tumor suppressor genes can start angiogenic process. Different factors produced from stromal and tumor cells such as growth factors, cytokines, enzymes, and adhesion molecules are involved in this process, and the most potent of them is vascular endothelial growth factor (VEGF) [2]. Among the VEGF family, which consists of VEGF-A, VEGF-B, VEGF-C, VEGF-D, and VEGF-F, VEGF-A is a key angiogenic factor and is mostly used to promote angiogenic phenotype by a tumor [3]. VEGF-A is a dimeric glycoprotein with a molecular weight of 34¨C45£¿KDa, consisting of two subunits. Increased VEGF expression was seen in different physiologic and pathologic conditions which was associated with hypoxia [4]. VEGF is expressed in several malignant tumors which indicates its importance in angiogenesis process. Overexpression of VEGF was found in body fluids and solid tumors such as brain, colon, breast, kidney, bladder, lung, and oral cancer [5]. However, no investigations have
%U http://www.hindawi.com/journals/pri/2013/740582/